Preparing for the Bursting of the Psychedelic Hype Bubble.
David B. Yaden, James B. Potash, Roland R. Griffiths
JAMA Psychiatry October 1, 2022 DOI: 10.1001/jamapsychiatry.2022.2546 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Viewpoint Peer reviewed |
|---|---|
| Topics | Psychedelic-assisted therapy |
| Keywords | Psychedelic medicine Entheogenic treatment Hallucinogen-assisted therapy Mental health psychedelics Responsible psychedelic development Ethical psychedelic growth Sustainable psychedelic progress Regulated psychedelic innovation Psychedelic risk management Psychedelic scientific inquiry Ethical psychedelic frameworks Psychedelic regulatory guidelines Psychedelic training |
| Citations | 153 |
| Key points | Extreme shifts in public perception of psychedelics create impediments to clinical application, and claims not supported by evidence should be disputed. |
Abstract
This Viewpoint presents impediments to the clinical application of psychedelics created by extreme shifts in public perception while advocating further study and encouraging the dispute of claims not supported by available evidence.
Citations in the library
Cited by 136
- Single-Dose Psilocybin Treatment for Major Depressive Disorder JAMA August 31, 2023
- Canalization and plasticity in psychopathology Neuropharmacology December 27, 2022
- Transformative experience and informed consent to psychedelic-assisted psychotherapy Frontiers in Psychology May 26, 2023
- Dark loops: contagion effects, consistency and chemosocial matrices in psychedelic-assisted therapy trials Psychological Medicine July 19, 2023
- Effect of psilocybin versus escitalopram on depression symptom severity in patients with moderate-to-severe major depressive disorder: observational 6-month follow-up of a phase 2, double-blind, randomised, controlled trial EClinicalMedicine September 23, 2024
and 131 more in the library
Cites 10
- Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial Journal of Psychopharmacology November 30, 2016
- Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance Psychopharmacology July 7, 2006
- Trial of Psilocybin versus Escitalopram for Depression New England Journal of Medicine April 14, 2021
- Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder JAMA Psychiatry November 4, 2020
- Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects. Psychopharmacology December 1, 2011
and 5 more in the library